Ovarian cancer test could be gold standard in three years, says HealthLinx
This article was originally published in Clinica
Executive Summary
HealthLinx's second-generation ovarian cancer test could be the industry gold standard within the next three years, the Australian firm told Clinica. Futhermore, the company believes that its technology may have the potential to deliver the world's first community-based screening test for the disease.